Announces the successful completion of its stock swap offer for publicly owned shares of the French drug company Laboratoire Roger Bellon ("The Pink Sheet" Oct. 15, In Brief). Previously, Rhone-Poulenc Rorer had owned 76.2% of Roger Bellon, which generated $268 mil. in sales during 1989.
You may also be interested in...
The US green light for Alkindi is a big step for the UK biotech in its bid to become a world-leading specialty endocrinology business.
The agency sees its personnel compensation and benefits costs decrease for the first time in at least 16 years, while the overall FTE count continues to rise.
X-ray manufacturers and importers submitting Electronic Product Control reports will only need to submit their variance application package once.